ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRD vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Opus Genetics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: IRD 1 — MRK 9
■ METRIC PARITY
options-implied-move
—
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRD VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRD MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -11.61% 3.42% -15.03 MRK /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin -60.00% 28.10% -88.10 MRK /net-margins <GO>
Revenue Growth (YoY) 29.10% 1.30% +27.80 IRD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.19 -4.99 MRK /balance-sheet <GO>
Piotroski F-Score Quality 5/9 7/9 -2.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.3 51.7 -12.40 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $303.7M $361.02B -$360.72B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRD REV MRK REV IRD GROSS % MRK GROSS % IRD FCF MRK FCF
FY 2025 $14.2M $65.01B — 74.8% -$35.3M $12.36B
FY 2024 $11.0M $64.17B — 76.3% -$25.6M $18.10B
FY 2023 $19.0M $60.12B — — -$1.1M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRD // BETA —
MRK // BETA 0.92